• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Harnessing Beneficial Drug Interactions

Harnessing Beneficial Drug Interactions

November 1, 2018
Rehan Aziz, MD and Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD Associate Professor of Psychiatry and Neurology at Rutgers Robert Wood Johnson School of Medicine. Dr. Aziz has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Chris Aiken, MD Editor-in-Chief, The Carlat Psychiatry Report. Dr. Aiken has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.  

It’s nice when we can get our patients better with a single medication, but that’s not always possible. Sometimes the right combination of meds can do the trick, but studies of polypharmacy are scarce. In this article we dig through that research, small and limited as it is, to highlight a few useful combinations where the drug interaction can benefit your patient.

Stimulants with clonidine or guanfacine
Stimulants can raise blood pressure, which tends to be a problem as patients age. Adding an antihypertensive is a common solution, and two alpha-agonists, clonidine (Kapvay) and guanfacine (Intuniv), have FDA approval for both hypertension and ADHD. It sounds like a match made in heaven—but what do the data show?

This strategy was tested out in a randomized controlled trial in 207 children ages 7–14. It compared the combination of dex-methylphenidate XR (Focalin XR, 5–20 mg/day, average 15 mg/day) and guanfacine (1–3 mg/day, average 0.03 mg/kg/day) with each of those meds on their own. After 2 months, the combination strategy treated ADHD more effectively than either of the monotherapy arms. Side effects were also more favorable. The combined treatment had less blood pressure elevations than stimulant alone, and less fatigue than guanfacine ­monotherapy.

The combined treatment also had less QTc prolongation. That’s important, as QTc prolongation is partly responsible for the rare cases of sudden cardiac arrest on stimulants. In contrast, other ADHD augmentation strategies—bupropion, atomoxetine, and modafinil—can further elevate both blood pressure and QTc.

There was no apparent downside to this strategy, but the benefits were not very large, and neither drug completely reversed the side effects of the other (McCracken JT et al, J AACAP 2016;55(8):657–666).

TCPR recommendation: Combining stimulants and guanfacine (and possibly clonidine) is a sensible strategy in ADHD, particularly when cardiac risks are present.

Dopamine agonists and SSRIs
The dopamine agonists pramipexole (Mirapex) and ropinirole (Requip) are FDA-approved for restless leg syndrome (RLS) and have antidepressant qualities in their own right. Of the two, pramipexole is better studied in depression and has worked in small, controlled trials of both bipolar and unipolar depression. Further, in one trial, patients with hard-to-treat MDD who received pramipexole combined with an SSRI/SNRI achieved better response than patients taking an SSRI/SNRI and placebo (Cusin C et al, J Clin Psychiatry 2013;74(7):e636–e641).

In terms of side effects, serotonergic medications can sometimes cause RLS (Debattista CB et al, J Clin Psychopharm 2000;20(2):274–275). Pramipexole can treat SSRI-induced RLS. That benefit, along with its ability to augment SSRIs in treatment-resistant depression, makes this an intriguing combination.

When using pramipexole, starting low (around 0.125–0.25 mg per day) and increasing the dose slowly (by 0.25 mg every week) helps reduce nausea and orthostasis, two common side effects with this drug. Sedation is also possible, and there have been rare reports of visual hallucinations and compulsive behaviors such as gambling (Aiken CB, J Clin Psychiatry 2007;68(8):1230–1236).

TCPR recommendation: When patients complain of restless legs on serotonergic antidepressants, try a low dose of pramipexole for RLS. The dose can be raised if depressive symptoms ­persist.

Lithium and carbamazepine
Lithium and carbamazepine might not be the first drugs you’d think about combining, given that they both have significant adverse reactions and potential toxicity. But there are reports that these drugs can cancel out some of each other’s side effects. In particular, they have opposite effects on sodium and white blood count. Carbamazepine can lower sodium by raising SIADH, whereas lithium raises sodium by causing the opposite syndrome, diabetes insipidus. Small studies have concluded that lithium protects against hyponatremia on carbamazepine (Vieweg V et al, Am J Psych 1987;144(7):943–947).

In addition, carbamazepine can cause a potentially dangerous neutropenia, while lithium increases white blood cell production. In a placebo-controlled study, lithium successfully reversed the neutropenia that was induced by carbamazepine (Kramlinger KG and Post RM, Am J Psych 1990;147(5):615–620).

Beyond side effect neutralization, there may be an efficacy advantage with this combination. There are open-label studies of patients who did not respond to lithium or carbamazepine alone but who then responded to the two drugs together (Lipinski JF et al, Am J Psych 1982;139(7):948–949). The combination is particularly helpful in rapid-cycling bipolar disorder (Strömgren LS, Comprehensive Psych 1990;31(3):261–265).

This combination is not without its risks. Lithium and carbamazepine can have additive effects toward hypothyroidism, and there are rare reports of neurotoxicity even with normal plasma levels of each drug (Kim MD et al, Jefferson J Psych 1988;6(2):63–72).

TCPR recommendation: For patients with rapid-cycling or treatment-resistant bipolar disorder, the combination of carbamazepine and lithium can be effective, even if neither of those meds worked on their own. Lithium can help reverse drops in white blood cells, neutrophils, and sodium caused by carbamazepine.

Clozapine and fluvoxamine
Clozapine is one of the less friendly atypicals when it comes to weight gain, diabetes, and triglycerides. Most of those metabolic side effects are not due to clozapine itself but to its metabolite, norclozapine. Fluvoxamine (Luvox) blocks the conversion of clozapine into norclozapine by inhibiting the CYP1A2 enzyme. In theory, combining these drugs creates a more tolerable version of clozapine.

This strategy has been used since the 1990s, but it wasn’t tested in a randomized controlled trial until this year. In that study, 85 patients with schizophrenia were given clozapine either as monotherapy (300 mg/day) or in combination (clozapine 100 mg/day with fluvoxamine 50 mg/day). After 3 months, the combination group had significantly less weight gain, insulin resistance, glucose, and triglycerides compared to clozapine monotherapy. The combined group also had greater improvement on the PANSS psychopathology scores.

Serum levels of clozapine were similar in both groups, but as predicted, the norclozapine metabolite was lower in the combination group (Lu ML et al, Schizophrenia Research 2018;193:126–133).

TCPR recommendation: For patients who need to stay on clozapine but have significant side effects with the medication, you could consider carefully adding fluvoxamine. However, drug interactions are difficult to predict, so check a clozapine level before and after adding fluvoxamine, and follow it regularly while using them together.

TCPR Verdict: When polypharmacy is needed, look for combinations that reduce the side effect burden instead of raising it.
General Psychiatry
KEYWORDS practice_tools_and_tips psychopharmacology_tips registered-articles
    Rehan Aziz, MD

    Breaking the Silence: Addressing the Hidden Crisis of Elder Abuse

    More from this author
    Aiken eic 150x150
    Chris Aiken, MD

    Ketamine Assisted Therapy Part I

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Drug Metabolism, TCPR, November/December 2018
    New Approvals for TMS
    Is Clozapine the Next Step After a Single Failed Antipsychotic Trial?
    Does TMS Really Work in Depression?
    Probiotics for Bipolar Disorder
    Ask the Editor: Which Antipsychotic Is Best When Patients Complain of Akathisia?
    Effects of Drug Interactions
    Harnessing Beneficial Drug Interactions
    New Stimulants: From Remixed Amphetamines to Bedtime Ritalin
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.